InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.145 0.01 (7.41%)+
Announcement
Release
8 May 2026 8:29AM
Price at Release
$0.135
Full Release
download
Summary
Amplia Therapeutics Limited, in collaboration with the Australia New Zealand Gynaecological Oncology Group (ANZGOG), announced a new clinical study targeting ovarian cancer. The study, known as the PRROSE trial, will assess the safety and efficacy of narmafotinib combined with standard chemotherapy (carboplatin and paclitaxel) in patients with high-grade serous ovarian cancer who have not responded to initial platinum-based chemotherapy. The trial aims to enroll 15-20 patients across Australia and New Zealand, focusing on increasing surgical success rates and analyzing biomarkers to understand the mechanism of action of narmafotinib. Dr. Chris Burns, CEO of Amplia, expressed enthusiasm for the collaboration and the potential for FAK inhibitors in addressing significant unmet medical needs in ovarian cancer treatment.
Key Points
  • Amplia Therapeutics Limited and ANZGOG have announced a new clinical study on ovarian cancer.
  • The study will evaluate the safety of narmafotinib combined with standard chemotherapy in high-grade serous ovarian cancer patients.
  • The trial is named PRROSE and will be conducted in Australia and New Zealand.
  • The study focuses on patients who did not respond to standard platinum-based chemotherapy.
  • Approximately 15-20 patients are expected to enroll in this trial.
  • The study aims to explore if adding narmafotinib can increase surgical success rates.
  • Biomarker analysis will be conducted to understand narmafotinib's mechanism of action.
  • Dr. Chris Burns from Amplia highlighted the potential of FAK inhibitors in treating ovarian cancer.
  • ANZGOG's collaborative network supports the study, which may change clinical practices in gynecological cancers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.